Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
Although earnings declined 10% year over, the figure still beat the Zacks Consensus Estimate of $1.13. Total revenues of $31.0 million were down 30% from the year-ago quarter's levels. The reported figure missed the Zacks Consensus Estimate of $32.5 million. The downside in earnings and sales was due to the receipt of a milestone payment from Travere Therapeutics TVTX in the year-ago period. Quarter in Detail Royalty revenues were up 8% year over year to $19.1 million in the first quarter. The upside was driven by increased royalties from Amgen's Kyprolis, Jazz Pharmaceuticals' Rylaze, Merck's Vaxneuvance and Travere's Filspari. Total Captisol sales were down 13% year over year to $9.2 million in the reported quarter due to the unfavorable timing of customer orders. During the quarter, the company did not record any Captisol sales related to COVID-19. Contract revenues were down 83% year over year to $2.6 million in the first quarter. The downside was caused by the receipt
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade [Yahoo! Finance]Yahoo! Finance
- Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $144.00 price target on the stock.MarketBeat
LGND
Earnings
- 5/7/24 - Beat
LGND
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/17/24 - Form 144
- LGND's page on the SEC website